Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
PC9, PC9/gef, H3255, and H1975 cell lines are not able to proliferate or remain viable when exposed to pervoside (50–5000 nM) for 24 hours [1]. Combining Peruvoside (0.005-0.5 μM) with Gefitinib (0.01~0.5 μM) for 72 hours increased the sensitivity of A549, PC9/gef, and H1975 cells to gefitinib [1]. Cycling and chemotherapy are induced in MCF-7, HpG2, and A549 cells by perovoside (0-100 μM, 24 hours) [2.
|
---|---|
ln Vivo |
Tumor model growth inhibition is achieved by perovoside (0.1 mg/kg, intraperitoneal injection; once daily for 28 days in a row) [1]. Peritoneal injection of 0.59 mg/kg, administered once day for seven days, decreases EV-
|
Cell Assay |
Cell proliferation assay[1]
Cell Types: PC9, PC9/gef, H3255 and H1975 Cell line Tested Concentrations: 0, 0.01, 0.05, 0.1, 0.5, 1 μM Incubation Duration: 24, 48, 72, 96 hrs (hours). Experimental Results: Viability of TKI-sensitive and TKI-resistant cell lines was inhibited at all time points tested. Inhibits the viability and proliferation of EGFR mutant lung cancer cells. The 24-hour IC50 of A549, PC9, PC9/gef, H3255, H1975 and BEAS-2B cells are 48 nM, 74 nM, 67 nM, 143 nM, 277 nM and 428 nM respectively. respectively. Dramatically inhibited the proliferation of A549 (48, 72 and 96 hrs (hours)) and H3255 (24, 48, 72 and 96 hrs (hours)) lung cancer cells. Cell viability assay[1] Cell Types: A549, PC9/gef and H1975 Cell Line Tested Concentrations: 0.005, 0.0075, 0.01, 0.025, 0.05, 0.5 μM (combined with 0.01, 0.05, 0.1, 0.25, 0.5 μM gefitinib) Incubation Duration: 72 hrs (hours). Experimental Results: The combination of 0.005, 0.075 or 0.01μM gefitinib and low-dose (0.01 or 0.05μM) gefitinib had a synergistic effect on A549 cells. Improves the sensitivity o |
Animal Protocol |
Animal/Disease Models: Lung cancer mouse model [1]
Doses: 0.1 mg/kg Route of Administration: intraperitoneal (ip) injection; A71 infection model hybridization[4]. one time/day for 28 days. Experimental Results: The tumor size was diminished to 129.9 mm3, which was Dramatically smaller than the control group (348 mm3). The levels of phosphorylated Src Y419 were Dramatically diminished in tumor tissues compared with control tissues. Animal/Disease Models: EV-A71 infection mouse model [4] Doses: 0.59 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 7 days Experimental Results: Based on body weight, activity, breathing, movement and dehydration and other physical symptoms , clinical scores were Dramatically diminished. It demonstrated an approximately 6-log reduction in virus titer and an efficacy of 99.9% in inhibiting the virus. |
References |
[1]. Lai Y, et al. Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways. Am J Cancer Res. 2022 Jun 15;12(6):2576-2593.
[2]. Reddy D, et al. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sci. 2020 Jan 15;241:117147. doi: 10.1016/j.lfs.2019.117147. Epub 2019 Dec 9. PMID: 31830480. [3]. Feng Q, et al. Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death. Molecules. 2016 Apr 22;21(4):534. [4]. Wu KX, et al. The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses. Acta Pharm Sin B. 2023 May;13(5):2039-2055. |
Molecular Formula |
C30H44O9
|
---|---|
Molecular Weight |
548.66496
|
CAS # |
1182-87-2
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]5(C)[C@H](CC[C@]45O)C6=CC(=O)OC6)C2)O)OC)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8226 mL | 9.1129 mL | 18.2259 mL | |
5 mM | 0.3645 mL | 1.8226 mL | 3.6452 mL | |
10 mM | 0.1823 mL | 0.9113 mL | 1.8226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.